Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi huoxue powder is a Traditional Chinese Medicine (TCM) formulation developed by the Guangdong Provincial Hospital of Chinese Medicine for the treatment of sepsis and pneumonia. The formula is based on the TCM principle of replenishing Qi and activating blood circulation (Yiqi Huoxue) to address the systemic inflammatory response and microcirculatory dysfunction characteristic of critical illness. It typically contains a combination of herbs such as *Astragalus membranaceus* and *Salvia miltiorrhiza*. Pharmacologically, the powder works by downregulating pro-inflammatory cytokines, including tumor necrosis factor (TNF) and interleukin-6 (IL-6), and inhibiting the NF-kappaB signaling pathway. Clinical research at the developer's institution has focused on its ability to protect against sepsis-induced organ injury, particularly in the lungs and heart, and to improve overall patient prognosis in intensive care settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yiqi huoxue powder.